Kaiser Stephanie M, Arepalli Sruthi, Ehlers Justis P
Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
J Exp Pharmacol. 2021 Sep 29;13:905-912. doi: 10.2147/JEP.S259298. eCollection 2021.
Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.
年龄相关性黄斑变性（AMD）是发达国家法定失明的最常见原因。新生血管性（即湿性）AMD目前采用玻璃体腔内治疗。传统治疗方法（即贝伐单抗、雷珠单抗、阿柏西普）提供高效治疗，但也可能需要频繁给药。更新的以及未来的抗血管内皮生长因子（VEGF）疗法旨在通过延长半衰期或端口给药系统（布罗利珠单抗、康柏西普、KSI-301、雷珠单抗）来减少注射频率。本综述概述了当前的抗VEGF治疗方法及其持续时间可能延长的方式。
